Urinary angiotensinogen reflects the activity of intrarenal reninangiotensin system in patients with IgA nephropathy

Nephrology Dialysis Transplantation

Volumn 26, Issue 1, 2011, Pages 170-177

  Nishiyama, Akira ^a   Konishi, Yoshio ^b   Ohashi, Naro ^c   Morikawa, Takashi ^b   Urushihara, Maki ^c   Maeda, Isseki ^b   Hamada, Masahiro ^b   Kishida, Masatsugu ^b   Hitomi, Hirofumi ^a   Shirahashi, Nobuo ^d   Kobori, Hiroyuki ^c   Imanishi, Masahito ^b  

^a KAGAWA UNIVERSITY   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

angiotensin II; angiotensinogen; IgA nephropathy; urinary biomarker; valsartan

Indexed keywords

ANGIOTENSIN II; ANGIOTENSINOGEN; VALSARTAN;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GLOMERULUS FILTRATION; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOREACTIVITY; KIDNEY BLOOD FLOW; KIDNEY PARENCHYMA; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URINE LEVEL;

ANGIOTENSINOGEN; BIOLOGICAL MARKERS; BLOOD PRESSURE; CASE-CONTROL STUDIES; CREATININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM;

EID: 78650656643     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq371     Document Type: Article

References (33)

1. Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs amlodi-pine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719-2728
2. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
3. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
4. Makino H, Haneda M, Babazono T et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diab Care 2007; 30: 1577-1578
5. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678
6. Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115: 114-126
7. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187 (Pubitemid 46924065)
8. Ogihara T, Kikuchi K, Matsuoka H et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107
9. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572
10. Navar LG, Harrison-Bernard LM, Nishiyama A et al. Regulation of intrarenal angiotensin II in hypertension. Hypertension 2002; 39: 316-322
11. Kobori H, Nangaku M, Navar LG et al. The intrarenal renin- angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59: 251-287
12. Kobori H, Ozawa Y, Suzaki Y et al. Young Scholars Award Lecture: intratubular angiotensinogen in hypertension and kidney diseases. Am J Hypertens 2006; 19: 541-550
13. Kobori H, Ozawa Y, Satou R et al. Kidney-specific enhancement of ANG II stimulates endogenous intrarenal angiotensinogen in gene-targeted mice. Am J Physiol Ren Physiol 2007; 293: F938-F945
14. Kobori H, Harrison-Bernard LM, Navar LG. Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int 2002; 61: 579-585
15. Kobori H, Nishiyama A, Harrison-Bernard LM et al. Urinary angio-tensinogen as an indicator of intrarenal angiotensin status in hypertension. Hypertension 2003; 41: 42-49
16. Yamamoto T, Nakagawa T, Suzuki H et al. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol 2007; 18: 1558-1565
17. Katsurada A, Hagiwara Y, Miyashita K et al. Novel sandwich ELISA for human angiotensinogen. Am J Physiol Ren Physiol 2007; 293: F956-F960
18. Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med 1990; 89: 209-215
19. Russo D, Minutolo R, Pisani A et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001; 38: 18-25
20. Hilgers KF, Mann JF. ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 2002; 13: 1100-1108
21. Coppo R, Peruzzi L, Amore A et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 2007; 18: 1880-1888
22. Ohashi N, Katsurada A, Miyata K et al. The role of activated in-trarenal reactive oxygen species and renin-angiotensin system in IgA nephropathy model mice. Clin Exp Pharmacol Physiol 2009
23. Kobori H, Katsurada A, Ozawa Y et al. Enhanced intrarenal oxidative stress and angiotensinogen in IgA nephropathy patients. Biochem Biophys Res Commun 2007; 358: 156-163
24. Takamatsu M, Urushihara M, Kondo S et al. Glomerular angioten-sinogen protein is enhanced in pediatric IgA nephropathy. Pediatr Nephrol 2008; 23: 1257-1267
25. Tomino Y, Sakai H. Clinical guidelines for immunoglobulin A (IgA) nephropathy in Japan, second version. Clin Exp Nephrol 2003; 7: 93-97
26. Kobori H, Ozawa Y, Suzaki Y et al. Enhanced intrarenal angiotensi-nogen contributes to early renal injury in spontaneously hypertensive rats. J Am Soc Nephrol 2005; 16: 2073-2080
27. Sun GP, Kohno M, Guo P et al. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 2006; 17: 2193-2201
28. Kohda Y, Murakami H, Moe OW et al. Analysis of segmental renal gene expression by laser capture microdissection. Kidney Int 2000; 57: 321-331
29. Betsuyaku T, Griffin GL, Watson MA et al. Laser capture microdis-section and real-time reverse transcriptase/polymerase chain reaction of bronchiolar epithelium after bleomycin. Am J Respir Cell Mol Biol 2001; 25: 278-284
30. Kobori H, Alper AB Jr, Shenava R et al. Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients. Hypertension 2009; 53: 344-350
31. Konishi Y, Morikawa T, Yasu T et al. Blunted response of the renin-angiotensin system and nitric oxide synthesis related to sodium sensitivity in immunoglobulin A nephropathy. Hypertens Res 2004; 27: 7-13
32. Coppo R, Amore A, Gianoglio B et al. Angiotensin II local hyper-reactivity in the progression of IgA nephropathy. Am J Kidney Dis 1993; 21: 593-602
33. Chan LY, Leung JC, Tang SC et al. Tubular expression of angiotensin II receptors and their regulation in IgA nephropathy. J Am Soc Nephrol 2005; 16: 2306-2317